This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
At the annual meeting of the American Academy of Otolaryngology–Head and Neck Surgery, San Diego, Calif, September 1990, David E. Eibling et al, San Antonio, Tex, presented their work with tumor-infiltrating lymphocytes in locally advanced squamous cell carcinoma of the head and neck.
Twenty-two patients with advanced squamous cell carcinoma of the head and neck were studied for a minimum of 30 months. Correlation between in situ characteristics of tumor-infiltrating lymphocytes and recurrent disease was investigated. At the time of surgery, tumor specimens were collected, snap frozen, and stained with immunoperoxidase. Monoclonal antibodies were used for identification and classification. A variety of head and neck sites were included in the study. Lymphocytes with the CD4+ marker were predominant in the parenchyma of tumors.
Twelve patients (55% ) developed recurrent disease from 4 to 18 months after therapy. There was a significant difference in recurrence rates between patients having greater than 20
PRATT MF. Tumor-Infiltrating Lymphocytes in Squamous Cell Carcinoma of the Head and Neck. Arch Otolaryngol Head Neck Surg. 1991;117(1):17. doi:10.1001/archotol.1991.01870130023002
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.